Following successful trials, Israeli biotech Kamada has launched its KamRAB anti-Rabies vaccine in 10 countries, including Israel. Kamada will now apply for a Biologics License Application (BLA) from the US FDA – the last step before offering a remedy for sale in the United States.

http://www.timesofisrael.com/israeli-firm-seeks-to-take-bite-out-of-rabies-vaccine-shortage/